Estrone 3-glucuronide chemiluminescence immunoassay (LIA) and 17beta estradiol radioimmunoassay (RIA) in the monitoring of superovulation for in vitro fertilization (IVF): correlation with follicular parameters and oocyte maturity.
Many works in the literature of the last years had reported that urinary approach to superovulation study is a suitable method to evaluate ovarian response to pharmacological stimulation. Before applying urinary determination of hormonal levels with a chemiluminescence immuno assay (LIA) method in early morning urine (EMU) samples, we had studied the correlation of RIA-LIA procedures with reference to follicular volumes at hCG day and to recovered oocyte maturity; in fact follicular growth and oocyte morphological features are the main parameters to evaluate a successful induced cycle. In our department the IVF cycles are daily monitored with RIA seric E2 and LIA E1-3G determination, besides ultrasound examination of follicular growth. We have studied E2 and E1-3G levels on the hCG administration day and their correlation with follicular areas and volumes; moreover, we have evaluated hormonal values on oocyte pick-up day with reference to recovered oocyte number and maturity. We have assumed as good timing for oocyte pick-up when more than 50% of recovered oocytes were of good quality (maturity score 4). We have observed that the highest pre ovulatory E1-3G value is consistent with the best timing for oocyte pick-up; it's possible to obtain a conversion coefficient follicular volumes and urinary E1-3G excretion. We have not found significant differences between plasmatic and urinary estrogenic parameters. It is important to remember the advantages connected by a not isotopic and not invasive method. The absence of discomfort for the patients may be a decisive factor to choose the monitoring method and LIA procedure may represent a valid alternative to RIA.
Rapi
S
S
Gynaecologic and Obstetric Department, University of Florence.
Fuzzi
B
B
Mannelli
M
M
Pratesi
S
S
Criscuoli
L
L
Pellegrini
S
S
Messeri
G
G
D000328:Adult; D002064:Buserelin / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood*; D004966:Estrogens, Conjugated (USP) / Q000652:urine*; D004970:Estrone / Q000031:analogs & derivatives* / Q000652:urine; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D007118:Immunoassay; D007247:Infertility, Female / Q000628:therapy; D008163:Luminescent Measurements; D008596:Menotropins / Q000627:therapeutic use; D009865:Oocytes / Q000637:transplantation*; D006080:Ovarian Follicle / Q000033:anatomy & histology / Q000502:physiology; D010062:Ovulation Induction / Q000379:methods; D011863:Radioimmunoassay; D012044:Regression Analysis; D013997:Time Factors
D006063:Chorionic Gonadotropin; D004966:Estrogens, Conjugated (USP); C015856:estrone-3-glucuronide; D004970:Estrone; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D008596:Menotropins; D002064:Buserelin